Arrowhead製藥 ARWR 深 滬
等待開盤 07-17 09:30:00 美东时间
18.30
+0.670
+3.80%
華盛通- 最 高18.43
- 今 開17.87
- 成交量 124.85万股
- 最 低 17.75
- 昨 收 17.63
- 總市值 25.25亿
- 52周最高 29.47
- 市盈率 靜 --
- 換手率 0.90%
- 52周最低 9.57
- 委 比 76.74%
- 總股本 1.38亿
- 歷史最高 93.66
- 量 比 0.76
- 振 幅 3.86%
- 歷史最低 1.22
- 每 手 1
- 風險率 4.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arrowhead Pharmaceuticals shares are trading higher after the company announced it has dosed the first patient for its YOSEMITE Phase 3 trial of RNAi-based Zodasiran.
Arrowhead Pharmaceuticals shares are trading higher after the company announced...
07-09 02:39
Pure Storage's new CFO gets praise from analysts
Pure Storage's (NYSE:PSTG) announcement on Tuesday that Tarek Robbiati will become its new Chief Financial Officer has received praise from some Wall Street analysts. Evercore ISI analyst Amit Daryan...
06-25 03:45
Pure Storage announces CFO appointment
Pure Storage (NYSE:PSTG) has named Tarek Robbiati as its new chief financial officer, effective immediately. Robbiati previously served as chief executive officer of RingCentral and CFO of Hewlett Pac...
06-24 21:09
Arrowhead Wraps Enrollment for 3 Key Trials on Fat-Busting Drug, Eyes FDA Decision in November
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions
06-23 19:32
Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'
Arrowhead Pharmaceuticals, Snowflake, Dover and Fluor are each in focus on today's edition of "Mad Money Lightning Round."
06-04 20:02
Voyager Technologies targets $319M IPO amid growth in space, defense
Voyager Technologies (VOYG) on Monday kicked off the roadshow for its initial public offering, aiming to raise up to $319 million as the company positions itself at the intersection of defense moderni...
06-03 01:14
Arrowhead Pharma Doses First Subjects In Phase 1/2a Clinical Trial Of ARO-ALK7, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Obesity
ARO-ALK7 is the first investigational RNAi therapeutic to enter clinical studies that targets a gene expressed in adipose tissueStudy initiation highlights Arrowhead's leadership in the delivery of siRNA to multiple
06-02 19:31
SA analyst downgrades: PLTR, PSTG, NTLA, ARWR
Here are the latest stock rating downgrades by Seeking Alpha analysts: Palantir (NASDAQ:PLTR). Hold to sell by Bay Area Ideas. "Despite strong fundamentals, Palantir's P/S ratio is extremely elevated,...
05-31 03:04
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
